Oncolytic Virus Immunotherapy Market Report 2025 (Global Edition)

Global Oncolytic Virus Immunotherapy Market Report 2024 Market Size Split by Type Outlook: (Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus, Others), by Route of Administration Outlook: (In...

Oncolytic Virus Immunotherapy Market Report Description

We have various report editions of Oncolytic Virus Immunotherapy Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Oncolytic Virus Immunotherapy Market Insights Video

Competitive Landscape of the Oncolytic Virus Immunotherapy Market

In the Oncolytic Virus Immunotherapy market's competitive landscape, numerous key competitors are driving innovation and growth. The companies are actively prioritizing research and development initiatives to expand their product portfolios, pioneer new therapies, and strengthen their market presence. Acquisitions, strategic alliances, and partnerships are frequently implemented to enhance competitiveness. Further, the market is becoming increasingly competitive due to the increasing investments in oncology research and technological advancements.

In January 2022, Siga Technologies disclosed that it has established a preclinical partnership with Bioarchitech to develop viral immunotherapy for cancer. The research collaboration entails examining the former's TPOXX (tecovirimat) in conjunction with the latter's vaccinia-based immunotherapy platform, which employs engineered antibodies and a variety of other proteins embedded with the oncolytic virus genome. (Source: https://www.contractpharma.com/contents/view_breaking-news/2022-07-15/siga-technologies-enters-collaboration-with-kalivir-immunotherapeutics/) In December 2021, Bionaut Labs announced a strategic partnership with Candel Therapeutics, Inc. to explore the potential of the former's remote-controlled microscale robotics to deliver the latter's oncolytic viral immunotherapy agents to brain tumours with precision. (Source: https://ir.candeltx.com/news-releases/news-release-details/bionaut-labs-and-candel-therapeutics-announce-strategic) In August 2021, the University of Chicago and the City of Hope entered into an exclusive license agreement with Calidi Biotherapeutics to collaborate on oncolytic virotherapy technology. (Source: https://www.calidibio.com/newsroom/post/calidi-biotherapeutics-announces-exclusive-license-agreement-with-city-of-hope-and-the-university-of-chicago-for-novel-oncolytic-virotherapy-technology)

Top Companies Market Share in Oncolytic Virus Immunotherapy Industry: (In no particular order of Rank)

• Amgen Inc.
• Creative Biolabs
• Daiichi Sankyo Company Limited
• Genelux Corporation
• Oncorus Inc.
• Replimune Inc.
• Siga Technologies
• Sorrento Therapeutics Inc.
• TILT Biotherapeutics
• Viralytics Ltd.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Oncolytic Virus Immunotherapy Market

Which Region Dominates the Oncolytic Virus Immunotherapy Market in 2024?

According to Cognitive Market Research, North America currently dominates the Oncolytic Virus Immunotherapys market, and the region is expected to have significant growth during the anticipated period. The increase in healthcare expenditures in countries like the United States, the availability of advanced immune-oncology medications, and the increasing awareness of a variety of cancer treatment options.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the anticipated period, with the greatest compound annual growth rate (CAGR) as a result of a substantial increase in the number of pharmaceutical manufacturing companies that specialize in cancer treatment.

The current report Scope analyzes Oncolytic Virus Immunotherapy Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Oncolytic Virus Immunotherapy

According to Cognitive Market Research, the global Oncolytic Virus Immunotherapy market size was estimated at USD 312.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 125.00 million in 2024 and will grow at a compound annual growth rate (CAGR) of 20.7% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Oncolytic Virus Immunotherapy market with a market size of USD 98.63 million in 2024 and is anticipated to grow at a CAGR of 20.5% during the projected period. The U.S. market's Enhanced investment in clinical trials and research and development.
• The Canada Oncolytic Virus Immunotherapy market had a market share of USD 15.00 million in 2024 and is anticipated to grow at a CAGR of 21.5% during the projected period. Canada’s Increasing geriatric population and increasing cancer case prevalence.
• The Mexico Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 21.2% during the projected period, with a market size of USD 11.38 million in 2024.

Europe Oncolytic Virus Immunotherapy

According to Cognitive Market Research, the global Oncolytic Virus Immunotherapy market size was estimated at USD 312.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 93.75 million in 2024 and will grow at a compound annual growth rate (CAGR) of 21.0% from 2024 to 2031.

• The United Kingdom's Oncolytic Virus Immunotherapy market had a market share of USD 15.75 million in 2024 and is anticipated to grow at a CAGR of 21.8% during the projected period. In the UK, Oncolytic Virus Immunotherapy sales see an upswing due to the increase in regulatory support and approvals.
• The France Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 20.2% during the projected period, with a market size of USD 8.63 million in 2024.
• According to Cognitive Market Research, the German Oncolytic Virus Immunotherapy market size was valued at USD 18.56 million in 2024 and is anticipated to grow at a CAGR of 21.2% during the projected period. In Germany, Oncolytic Virus Immunotherapy surged due to the Improvements in delivery systems through technological innovation.
• The Italy Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 20.4% during the projected period, with a market size of USD 8.06 million in 2024.
• The Russia Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 20.0% during the projected period, with a market size of USD 14.53 million in 2024.
• The Spain Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 20.1% during the projected period with a market size of USD 7.69 million in 2024
• The Luxembourg Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 21.1% during the projected period, with a market size of USD 2.91 million in 2024.
• The Portugal Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 20.8% during the projected period, with a market size of USD 1.97 million in 2024.
• The Greece Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 21.3% during the projected period, with a market size of USD 1.13 million in 2024.
• The Rest of Europe's Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 19.7% during the projected period, with a market size of USD 14.53 million in 2024.

Asia Pacific Oncolytic Virus Immunotherapy

According to Cognitive Market Research, the global Oncolytic Virus Immunotherapy market size was estimated at USD 312.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 71.88 million in 2024 and will grow at a compound annual growth rate (CAGR) of 24.5% from 2024 to 2031.

• According to Cognitive Market Research, the China Oncolytic Virus Immunotherapy market size was valued at USD 32.34 million in 2024 and is anticipated to grow at a CAGR of 24.0% during the projected period. Oncolytic Virus Immunotherapy surged in China due to Increased funding and the expansion of healthcare infrastructure.
• The Japan Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 23.0% during the projected period, with a market size of USD 9.92 million in 2024.
• The India Oncolytic Virus Immunotherapy market had a market share of USD 8.63 million in 2024 and is anticipated to grow at a CAGR of 26.3% during the projected period. India's increasing cost of healthcare and the emphasis on innovative cancer treatments.
• The South Korean Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 23.6% during the projected period, with a market size of USD 7.19 million in 2024.
• The Australian Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 24.2% during the projected period, with a market size of USD 3.74 million in 2024.
• The South East Asia Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 25.5% during the projected period, with a market size of USD 4.96 million in 2024.
• The Rest of Asia Pacific Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 24.3% during the projected period, with a market size of USD 5.10 million in 2024.

South America Oncolytic Virus Immunotherapy

According to Cognitive Market Research, the global Oncolytic Virus Immunotherapy market size was estimated at USD 312.5 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 15.63 million in 2024 and will grow at a compound annual growth rate (CAGR) of 21.9% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Oncolytic Virus Immunotherapy market size was valued at USD 6.69 million in 2024 and is anticipated to grow at a CAGR of 22.5% during the projected period. Oncolytic Virus Immunotherapy flourished in Brazil due to Enhanced funding for cancer research and development.
• Argentina's Oncolytic Virus Immunotherapy market had a market share of USD 2.63 million in 2024 and is anticipated to grow at a CAGR of 22.8% during the projected period. Argentina's increasing number of cancer instances.
• Colombia's Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 21.7% during the projected period, with a market size of USD 1.39 million in 2024.
• Peru's Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 22.1% during the projected period, with a market size of USD 1.28 million in 2024.
• Chile's Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 22.2% during the projected period, with a market size of USD 1.13 million in 2024.
• The Rest of Latin America's Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 21.0% during the projected period, with a market size of USD 2.52 million in 2024.

Middle East and Africa Oncolytic Virus Immunotherapy

According to Cognitive Market Research, the global Oncolytic Virus Immunotherapy market size was estimated at USD 312.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 6.25 million in 2024 and will grow at a compound annual growth rate (CAGR) of 22.2% from 2024 to 2031..

• The GCC Countries Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 23.0% during the projected period, with a market size of USD 2.68 million in 2024. Oncolytic Virus Immunotherapy sales flourish due to Increasing healthcare expenditures and an increase in the number of cancer cases.
• The Egypt Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 22.5% during the projected period, with a market size of USD 0.66 million in 2024.
• The South Africa Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 23.2% during the projected period, with a market size of USD 0.99 million in 2024. Oncolytic Virus Immunotherapy sales flourished in South Africa due to Significantly improved regulatory support and guidelines.
• The Turkey Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 21.7% during the projected period, with a market size of USD 0.54 million in 2024.
• The Nigeria Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 21.3% during the projected period, with a market size of USD 0.66 million in 2024.
• The Rest of the MEA Oncolytic Virus Immunotherapy market is anticipated to see growth at a CAGR of 21.2% during the projected period, with a market size of USD 0.74 million in 2024.

Oncolytic Virus Immunotherapy Market Analysis

How are Segments Performing in the Global Oncolytic Virus Immunotherapy Market?

Oncolytic Virus Immunotherapy Market Type Segment Analysis

According to Cognitive Market Research, Herpes Simplex Virus (HSV) are likely to dominate the Oncolytic Virus Immunotherapy Market over the projected period. HSV-based therapies, including T-VEC (Talimogene laherparepvec), have been licensed for the treatment of melanoma and have demonstrated substantial clinical efficacy, rendering them a popular choice among oncologists.

The Reovirus is the fastest-growing segment in the Oncolytic Virus Immunotherapy Market. The potential to be combined with other immunotherapies and their ability to target a wide spectrum of malignancies are the reasons why reovirus-based therapies are gaining attention. The promising preclinical and early clinical results are motivating a surge in research and development initiatives in this field.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Oncolytic Virus Immunotherapy Industry. Request a Free Sample PDF!

Oncolytic Virus Immunotherapy Market Route of Administration Segment Analysis

According to Cognitive Market Research, the Intratumoral segment holds the largest share of the market. The oncolytic virus is directly injected into the tumour using this method, which minimizes systemic exposure and enables localized treatment, thereby reducing the risk of adverse effects. The immune response within the tumour microenvironment is also improved by the localized approach, which is why it is the preferred method for many oncologists.

In the Oncolytic Virus Immunotherapy Market, the Intravenous sector has been expanding at a rapid pace. Oncolytic viruses that can be effectively administered through circulation have been developed as a result of recent advancements in viral engineering technology. The anticipated growth of this method is anticipated to be substantial as more of these therapies endure clinical trials and receive regulatory approval, enabling systemic treatment of metastatic and inaccessible malignancies.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Oncolytic Virus Immunotherapy Application Outlook: Segment Analysis

Oncolytic Virus Immunotherapy Market Application Segment Analysis

According to Cognitive Market Research, The Melanoma segment holds the largest market share. The widespread adoption and use of treatments such as T-VEC (Talimogene laherparepvec) in clinical practice are largely attributable to their approval and success in treating melanoma.

In the Oncolytic Virus Immunotherapy market, the rapidly growing sector is the Non-small Cell Lung Cancer (NSCLC) category. The rapid growth of NSCLC is being driven by the ongoing research into oncolytic virus therapies for this type of cancer and the increasing incidence of this cancer. It is anticipated that the demand for oncolytic virus treatments for NSCLC will increase substantially as more clinical trials demonstrate positive outcomes.

• Melanoma
• Non-small Cell Lung Cancer (NSCLC)
• Pancreatic Cancer
• Breast Cancer
• Others

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion